BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH CALSCALE:GREGORIAN PRODID:-//WordPress - MECv5.21.5//EN X-ORIGINAL-URL:https://cibm.ch/ BEGIN:VEVENT UID:MEC-0f7b2bb5d0c7e6209ecff113108f64cf@cibm.ch DTSTART:20220125T080000Z DTEND:20220125T093000Z DTSTAMP:20220119T100400Z CREATED:20220119 LAST-MODIFIED:20220119 SUMMARY:Breakfast & Science Seminar 21 DESCRIPTION:The first of the 2022 Breakfast and Science Seminar Series will be virtual. \nDate and time: Tuesday January 25th, 2022 – 9:00 to 10:30 CET\nLocation: Virtual on Zoom.\nProgram\n09:00 – 09:15 Welcome & Introduction\n09:15 – 10:00 How molecular imaging has changed our understanding of dementia\n\n \nValentina Garibotto,\nDivision of Nuclear Medicine and Molecular Imaging, Diagnostic Department, HUG. NIMTLab, Radiology Department, Faculty of Medicine, UNIGE. CIBM PET HUG UNIGE Section\nAbstract\nIn the last two decades, major efforts of the research community have focused on developing and validating biomarkers of disease processes in patients with cognitive disturbances. Molecular imaging with Positron emission tomography (PET) represents the only biomarker able to assess the presence and the topography of pathological deposits in the brain in vivo. These include namely amyloid and tau deposits, the two pathological hallmarks of Alzheimer’s Disease. This has led to a paradigm change in our understanding of the disease onset and progression, from a description mainly based on symptoms in patients, to the assessment of disease markers in cognitively normal individuals to define risk profiles. The talk will summarize the ongoing efforts of our group in Geneva, within a network of national and international collaborations, to contribute to these progresses in clinical practice.\nAbout the Speaker\nPr. Valentina Garibotto is division chair of nuclear medicine and molecular imaging at the University Hospitals of Geneva and associate professor at the Geneva University. She trained in Italy and Germany and then developed her clinical, research and teaching activity in Geneva. Her projects, mainly funded by the Swiss National Research foundation, the Velux Stiftung, the Schmidheiny and Aetas foundation, investigate molecular imaging, namely to guide diagnosis in neurodegenerative conditions, to discover causative and protecting factors and to support the development of novel therapeutic approaches. She has authored more than 190 peer reviewed articles (H index: 32, Web of Science) in the fields of clinical neuroimaging and nuclear medicine. She is Congress Chair Elected of the European Association of Nuclear Medicine, Chair of the Neuroimaging group of the Swiss Society of Nuclear Medicine and actively involved in a number of European initiatives developing and validating molecular imaging in cognitive disturbances.\n10:00-10:30 CIBM News and Updates\nSeminar Chair\nFrancois Lazeyras, Head of CIBM MRI HUG-UNIGE Clinical MR Imaging Sectionn\nPlease register by Monday January 24, 2022, 12:00\nTo join us on Zoom, please register at the following link:https://epfl.zoom.us/meeting/register/u5ctf–prjsiGdLCnbzjiKSMTeIRJGe0Nwpo\nAfter registering, you will receive a confirmation email containing information about joining the meeting.\nWe look forward to seeing you soon.\n \n X-ALT-DESC;FMTTYPE=text/html:
The first of the 2022 Breakfast and Science Seminar Series will be virtual.
Date and time: Tuesday January 25th, 2022 – 9:00 to 10:30 CET
Location: Virtual on Zoom.
09:00 – 09:15 Welcome & Introduction
09:15 – 10:00 How molecular imaging has changed our understanding of dementia
Abstract
In the last two decades, major efforts of the research community have focused on developing and validating biomarkers of disease processes in patients with cognitive disturbances. Molecular imaging with Positron emission tomography (PET) represents the only biomarker able to assess the presence and the topography of pathological deposits in the brain in vivo. These include namely amyloid and tau deposits, the two pathological hallmarks of Alzheimer’s Disease.
This has led to a paradigm change in our understanding of the disease onset and progression, from a description mainly based on symptoms in patients, to the assessment of disease markers in cognitively normal individuals to define risk profiles.
The talk will summarize the ongoing efforts of our group in Geneva, within a network of national and international collaborations, to contribute to these progresses in clinical practice.
About the Speaker
Pr. Valentina Garibotto is division chair of nuclear medicine and molecular imaging at the University Hospitals of Geneva and associate professor at the Geneva University. She trained in Italy and Germany and then developed her clinical, research and teaching activity in Geneva. Her projects, mainly funded by the Swiss National Research foundation, the Velux Stiftung, the Schmidheiny and Aetas foundation, investigate molecular imaging, namely to guide diagnosis in neurodegenerative conditions, to discover causative and protecting factors and to support the development of novel therapeutic approaches. She has authored more than 190 peer reviewed articles (H index: 32, Web of Science) in the fields of clinical neuroimaging and nuclear medicine. She is Congress Chair Elected of the European Association of Nuclear Medicine, Chair of the Neuroimaging group of the Swiss Society of Nuclear Medicine and actively involved in a number of European initiatives developing and validating molecular imaging in cognitive disturbances.
10:00-10:30 CIBM News and Updates
Please register by Monday January 24, 2022, 12:00
To join us on Zoom, please register at the following link:
https://epfl.zoom.us/meeting/register/u5ctf–prjsiGdLCnbzjiKSMTeIRJGe0Nwpo
After registering, you will receive a confirmation email containing information about joining the meeting.
We look forward to seeing you soon.
URL:https://cibm.ch/event/breakfast-science-seminar-21/ ORGANIZER;CN=:MAILTO: CATEGORIES:Breakfast&Science,Seminars LOCATION:Virtual END:VEVENT END:VCALENDAR